




UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov


U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/559,434	Oliver May	7601/84454

INTERNATIONAL APPLICATION NO.
PCT/EP04/05239

I.A. FILING DATE	PRIORITY DATE
05/15/2004	05/05/2004

42798

FITCH, EVEN, TABIN & FLANNERY
 P. O. BOX 65973
 WASHINGTON, DC 20035



CONFIRMATION NO. 1580
 371 FORMALITIES LETTER



OC000000018322807

Date Mailed: 03/24/2006

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The paper or compact disc copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e). Applicant must provide a substitute paper or compact disc copy of the "Sequence Listing", **as well as an amendment specifically directing its entry into the application** OR a substitute computer readable form (CRF) copy of the "Sequence Listing". These two items must be the same. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patent Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patent Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice **MUST** be returned with the response.

ANITA D JOHNSON


FETF. D.C.	
Sent To Docketing	
3-29-06	<i>AMS</i>
Date	Initials

Telephone: (703) 308-9140 EXT 226

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/559,434	PCT/EP04/05239	7601/84454

FORM PCT/DO/EO/922 (371 Formalities Notice)





FITCH EVEN TABIN & FLANNERY
INTELLECTUAL PROPERTY LAW | EST. IN 1859

I FW image
Box 500

Michael A. sanzo
Telephone: (202) 419-7013
Email: msanzo@fitcheven.com

May 17, 2006

Commissioner of Patents
U.S. Patent and Trademark Office
Customer Service Window, **MS PCT**
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Re: Amendment to Comply with Sequence Listing Rules
and Declaration and Power of Attorney
Appl. No.: 10/559,434
Filed: December 5, 2005
Title: **Screening Process for Hydantoin Racemases**
Inventor(s): May, *et al.*
Atty. Dkt.: 7601/84454

Dear Sir:

The following documents are being forwarded herewith for appropriate action by the U.S. Patent and Trademark Office:

1. A copy of the Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures w/Raw Sequence Listing Error Report attached;
2. Amendment to Comply with Sequence Listing Rules;
3. A paper copy of the substitute Sequence Listing;
4. A 3.5 inch diskette containing the computer readable form of the substitute Sequence Listing;
5. Three Declarations Under 37 C.F.R. § 1.63 and Power of Attorney executed by inventors Oliver May, Karlheinz Drauz and Stefan Buchholz (15 pages);
6. Supplemental Application Data Sheet; and

Commissioner of Patents
May 17, 2006
Page 2

7. Return postcard.

Applicants do not believe that any fee is due for the filing of these documents. However, the Director is hereby authorized to charge any fee deficiency with respect to this filing and any other fee required in connection with the present case, or credit any overpayment, to our Deposit Account No. 06-1135 under Order No. 7601/84454.

It is respectfully requested that the enclosed postcard be stamped with the date the enclosed documents are received by the PTO and that it be returned as soon as possible.

Very truly yours,

FITCH, EVEN, TABIN & FLANNERY

A handwritten signature in cursive script, reading "Michael A. Sanzo".

Michael A. Sanzo
Reg. No. 36,912
Attorney for Applicants

MAS:ct
Enclosures